About US
Contact us
-
FDA approves Janssen’s Sylvant to treat multicentric Castleman's diseaseThe US Food and Drug Administration has approved Janssen Biotech's Sylvant (siltuximab) to treat patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negativ2014/4/28
-
2014 PhexTour （Pharma Excipients Technical Application National Tour Seminar) 2nd station--Jinhua was successfully concluded2014 PhexTour （Pharma Excipients Technical Application National Tour Seminar)2nd station--Jinhua, was successfully concluded on 15April atHemei JinpanHotel.More than100 technical persons from 28 pharm2014/4/25
-
Eli Lilly's Cyramza becomes first FDA-approved gastric cancer drugEli Lilly has obtained US Food and Drug Administration approval for its Cyramza (ramucirumab) as a single-agent treatment for patients with advanced or metastatic gastric cancer or gastroesophageal ju2014/4/25
-
FDA grants orphan drug status to Bayer's bronchiectasis medicine Ciprofloxacin DPIThe US Food and Drug Administration (FDA) has granted orphan drug designation for Bayer HealthCare's investigational Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) to treat patients with2014/4/25
-
FDA Approves Merck’s Ragwitek (Short Ragweed Pollen Allergen Extract) Sublingual TabletMerckhas annoouncedthatFDA has approved Ragwitek (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (12 Amb a 1-U). Ragwitek is an allergen extract indicated as immunotherapy for the2014/4/24
-
Valeant and Pershing Square announce merger proposal with AllerganCanada-based Valeant Pharmaceuticals and US-based Pershing Square Capital Management have disclosed details of their offer to purchase Botox-maker Allergan for more than $45bn. Valeant is proposing t2014/4/24
-
NICE limits approval for Ferring's prostate cancer drug FirmagonThe UK National Institute for Health and Clinical Excellence (NICE) has recommended Ferring Pharmaceuticals' Firmagon (degarelix) as an option for treating advanced hormone-dependent prostate cancer.2014/4/23
-
GSK and Genmab obtain FDA clearance for Arzerra as first-line treatment for CLLGlaxoSmithKline (GSK) and Genmab have obtained US Food and Drug Administration (FDA) approval for Arzerra (ofatumumab) as first-line treatment in combination with chlorambucil for patients with chroni2014/4/23
-
The price is right for patient-switching on Biogen's new hemophilia med AlprolixWith a pair of long-actinghemophiliameds on the way, Biogen Idec ($BIIB) appears poised to shake up the market for the bleeding disease. And though recently approvedAlprolixhas yet to launch, it has a2014/4/22
-
Full steam ahead for Copaxone copies as SCOTUS denies Teva's bid for delayLast week, generics makers asked the Supreme Court to let them launch their copies of Teva's Copaxone while it hears the Israeli company's appeal over the drug's patents. Now, they'll likely get that2014/4/22